Four genomic alterations were detected in EGFR (A822T, R776H, S768N, T790M), and the T790M variant has been described in advanced non-small cell lung cancer (NSCLC) as an acquired variant associated with Tyrosine Kinase Inhibitors (TKIs) resistance (59, 60). This evidence concerns the gene EGFR and non-small cell lung carcinoma.